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Summary 
Studies were undertaken to determine whether interleukin 10, (Ibl0) a cytokine shown to inhibit 
interferon 3' (IFN-~/) production, was involved in Tryfanosoma cruzi infections in mice. Exogenous 
IFN-3, protects mice from fatal infection with T. ctuzi. Furthermore, resistant B6D2 mice developed 
fatal T. cruzi infections when treated with neutralizing anti-IFN-3, monoclonal antibody (mAb). 
Thus, endogenous as well as exogenous IFN-3' is important in mediating resistance to this parasite. 
Because both T. cruzi-susceptible  (B6) and -resistant (B6D2)  mouse strains  produced IFN-3, 
during acute infection, we looked for the concomitant production of mediators that could interfere 
with IFN-3,-mediated resistance to T. cruzi. We found that IL-10-specific mRNA was produced 
in the spleens of mice with acute T. cruzi infections.  In addition, spleen cell culture supernatants 
from infected B6 mice, and to a lesser extent B6D2 mice, elaborated  an inhibitor(s) of IFN-3' 
production. This inhibitor(s) was neutralized by anti-Ibl0 mAb. These experiments demonstrated 
the production of biologically active IL-10 during T. cruzi infection. In further studies in vitro, 
it was shown that IL-10 blocked the ability of IFN-'y to inhibit the intraceUular replication of 
T. cruzi in mouse peritoneal macrophages. Thus, in addition to its known ability to inhibit the 
production of IFN-% Ibl0 (cytokine synthesis inhibitory factor),  may also inhibit the effects 
of IFN-% These experiments demonstrate that IL-10 is produced during infection with a protozoan 
parasite and suggest a regulatory role for this cytokine in the mediation of susceptibility to acute 
disease. 
T 
he intraceUular protozoan parasite Trypanosoma cruzi causes 
Chagas' disease in humans. Infection with this hemo- 
flagellate has widely variable outcomes, determined  by factors 
unknown. Human infections may be subclinical, often charac- 
terized by a prolonged indeterminate phase with only a posi- 
tive serology to indicate the presence of parasites. Infection 
may also lead to acute disease with fatal outcome or, more 
commonly, the development of chronic disease with severe 
associated pathologies. In mice, different inbred strains may 
develop fatal or very mild infections when inoculated with 
the same T. cruzi isolate  (1, 2). Similarly, different T. cruzi 
isolates produce variable courses of infection within a given 
mouse strain (3). 
Two interconnected aspects of the immune response during 
experimental T. cruzi infection have been the subjects of con- 
siderable study. One is the nature of the protective host re- 
sponse to the parasite and the other is analysis of the pro- 
found immune depression that accompanies both acute and 
chronic infections. The latter is associated with defective mac- 
rophage (4) and T  cell function (5, 6), including a lack of 
Ib2 production and utilization (7-11). Immune responses can 
be  effectively  restored  in  infected mice with  exogenous 
cytokines, including IL-1 (12), IL-2 (7-9), and GM-CSF (4). 
It is not understood whether the immune depression pro- 
vokes or results from infection-associated  pathology. 
The roles of cytokines in resistance and susceptibility to 
T. cruzi are only superficially understood. Macrophage acti- 
vation by GM-CSF (13), IFN-~/(14, 15), or TNF (16) leads 
to inhibition of the replication of this parasite in vitro. Of 
these cytokines, IFN-3' has been most closely associated with 
host resistance. Treatment of infected animals with IFN-3, 
prevents acute disease, immune depression, and death induced 
by T. cruzi infection (17). Conversely, TGF-/3, a potent mac- 
rophage deactivator (18), may counteract the effects of IFN-3, 
during T. ctuzi infection (19). In this report, we document 
the necessity for endogenous IFN-3' in controlling T. cruzi 
infection in resistant mice. In addition, we provide evidence 
that another cytokine, II..10 (cytokine synthesis inhibitory 
factor [CSIF]I), may, by interfering with IFN-3' production 
1  Abbreviation used in this paper: CSIF, cytokine  synthesis  inhibitory  factor. 
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results of this study implicate this recently described cytokine 
(20,  21) in the regulation  of an infectious disease. 
Materials  and Methods 
Mice.  Female  C57B1/6J (B6), (C57B1/6J  x  DBA)F1 (B6D2), 
and BALB/c mice, 8 wk of age, were purchased from The Jackson 
Laboratory (Bar Harbor,  ME). 
Parasites.  A clone of the Tulahuen strain of T. cruzi, designated 
in accordance with the World Health Organization  classification 
as MHOM/CH/00/Tuhhuen C2 (13), was used in all experiments. 
Mice were infected i.p. with 103 trypomastigotes  grown in and 
purified from rat myoblast cells (L6E9). 
Immune Reagents.  Neutralizing anti-MuIFN-3~ and IIA0 mAbs 
were obtained from ascites collected from nude mice inoculated 
with rat hybridomas XMG 1.2 (22, provided by DNAX Corp., 
Palo Alto,  CA) or SXC1 (23, provided by Dr.  Tim Mosmann, 
University of Alberta, Edmonton,  Alberta,  Canada). The mAbs 
were concentrated from nude mouse ascites by ammonium sulfate 
precipitation and dialyzed against PBS. Recombinant murine (rMu)- 
IFN-~/(5.2  x  106 U/mg protein)  was provided by Genentech, 
Inc. (San Francisco, CA) as protein purified to homogeneity from 
Escherichia coli. 
rlLlO.  Ibl0 cDNA was cloned from RNA from the 7B9 rou- 
tine T cell clone (24) by PCR, using oligonudeotide primers de- 
signed from the IL-10 gene sequence (21). IL-10 was expressed in 
COS cells using the pDC302 vector previously described (24). COS 
cell supernatant  containing  rib10 (200 U/ml) and control COS 
cell supernatant  were used in these studies. Units of rIL-10 were 
determined  using  the IFN-)" inhibition  assay described below. 
Northern Blot.  Total  RNA was isolated from mouse spleen cell 
lysate using a guanidine thiocyanate method (25). Samples were 
analyzed on 1.5 % formaldehyde-denaturing agarose gels and trans- 
ferred by capillary blotting onto Zeta Probe membrane (Bio-Rad 
Laboratories, Richmond, CA) using 50 mM NaOH (26). The mem- 
brane was rinsed in 2x SSC, air-dried, and ultraviolet cross-linked. 
Filters were prehybridized at 60~  as previously described, (27) 
except that  the salt used was 6x  SSC. Labeled IL-10 probe was 
prepared by the random priming  method, as described (28), and 
added directly to the prehybridization mix at 2  x  106 cpm/ml of 
solution, and incubation continued for 16 h at 60~  Posthybridi- 
zation washes were twice at 65~  for 20 min with each of 2x 
and 0.Sx  SSC containing  0.1%  SDS. 
IFN-~/Inhibition (CSIF) Assay.  Spleen  cells from normal or in- 
fected animals at different days after infection were aseptically re- 
moved, washed, and adjusted to 5  x  106 lcukocytes/ml in RPMI 
1640 (Gibco Laboratories, Grand Island, NY), supplemented with 
5% FCS serum (Cdlect Gold; Flow Labs, McLean, VA), 100 U/ml 
of penicillin, 100/~g/ml streptomycin, and 5 mM of 2-ME (all from 
Sigma Chemical Co., St. Louis, MO). The cells were incubated 
for the time indicated in 24-well plates (Costar  Data Packaging 
Corp., Cambridge, MA). Supernatants from triplicate cultures were 
tested for CSIF activity after depletion of IFN-~/with XMG 1.2 
antibody covalently bound to AFFI-Gd (Bio-Rad Laboratories). 
Verification of IFN--y depletion was determined using a sandwich 
ELISA for mouse IFN-% 
The CSIF assay was performed using the BDT.7 cell line, main- 
tained by stimulation  with irradiated allogeneic mouse (DBA/2 
or BALB/c) spleen cells and Ib2. Resting (7 d poststimulation) 
cells were  added  to  dilutions  of test  supernatants  at  2  x  103 
cells/well with irradiated allogeneic stimulator cells (5  x  llY/well) 
in 1 ml complete medium (dMEM supplemented with antibiotics, 
Na pyruvate, 2-ME, glutamine, and 5% FCS). After a 24-h incu- 
bation, supernatants were collected for determination of IFN-3' by 
ELISA. 
Macrophage Microbicidal Activity.  Peritoneal macrophages were 
harvested from BALB/c mice previously injected with 1 ml of 6% 
sodium caseinate in saline i.p. (Eastman Kodak Company, Roch- 
ester, NY). The calls were infected with T. cruzi for the determina- 
tion ofintracdlular  growth and inhibition thereof as described (13). 
Results 
The Importance of Endogenous IFN-'y in Control of T. cruzi 
Infection.  To address the role of cytokines in resistance or 
susceptibility to T. cruzi infection, we developed a modal using 
two inbred mouse strains.  B6 mice are highly susceptible to 
the Tulahuen  strain,  while B6D2 mice are highly resistant 
(Fig.  1). Both mouse strains developed parasitemia,  spleno- 
megaly, and splenic parasite burdens. Using this system, we 
examined the role of IFN-3, and Ibl0 during acute infection. 
Although we have established the importance of IFN-"/in 
protection from acute T. cruzi infection (17), it has not been 
demonstrated that endogenously produced IFN-3, is essen- 
tial in mediating  protection from fatal  disease in a geneti- 
cally resistant host. We therefore treated both susceptible B6 
and resistant B6D2 mice with anti-IFN-3, mAb and looked 
for effects on the course of acute  T. cruzi  infection.  Treat- 
ment with anti-IFN-3, mAb altered the course of infection 
by significantly increasing parasitemia in both groups (Fig. 
1 A). Most dramatically, resistant B6D2 mice were rendered 
susceptible to acute T. cruzi infection, with 100% mortality, 
after anti-IFN-'t  treatment  (Fig.  1 B). These experiments 
established the importance of endogenous IFN-3' in control- 
ling acute infection,  and suggested that genetic resistance could 
the be mediated at least in part by IFN-% 
IFN-3/ Production by Resistant and Susceptible Mice during 
T. cruzi Infection.  Based on these findings,  and supported 
by our previous observations that the administration of IFN-~/ 
could prevent fatal infections in susceptible mice, we exam- 
ined IFN-'y production during the course of T. cruzi infec- 
tion in B6 and B6D2 mice. To test for secreted IFN-% spleen 
cells were cultured from mice during progressive days after 
infection and stimulated in vitro with Con A. Mitogen stim- 
ulation led to increased IFN-3, production in both B6 and 
B6D2 mice, which peaked during the acute phase (days 10-30) 
of the infection (not shown).  Spleen ceils from susceptible 
B6 mice, but not resistant B6D2 mice, produced detectable 
IFN-3, during the acute phase of infection without stimula- 
tion  (not  shown). 
Production of lL.lO mRNA during T. cruzi Infection.  Endo- 
genously produced IFNw failed to protect susceptible B6 mice, 
even though we and others (29) have shown that the IFN-3, 
produced by susceptible mice is biologically active in vitro. 
One reason for this may be that susceptible mice fail to pro- 
duce IFN-), during the very early stage of infection. Another 
is that molecules that inhibit the effects of IFN-'r are pro- 
duced during infection. Among the cytokines, Ibl0 may in- 
hibit the production of IFN-',/(21),  as well as the effects of 
cytokines on macrophage  activation  (30). 
To evaluate production of IL-10 mRNA, spleen cell lysates 
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treatment in resistant B6D2 (circles) 
and susceptible B6 (triangles) mice 
infected with T. cruz/. Mice were 
treated with 1 mg XMG 1.2 (closed 
symbo/s)  or saline (open  symbo/s) I d 
before and 3 d after intraperitoneal 
infection with 10  3 trypomastigotes. 
Parafitemia~ (A) and mortality (B) 
were determined at indicated days 
after infection.  Each  point (mean + 
SEM) represents  six  mice.  Mice 
treated  with  XMG  1.2  had 
parasitemias significantly higher (p 
< 0.05) than control mice at day 10 
and beyond. In B, no mortality was 
seen in salinetreated B6D2 mice, as 
compared with 100% mortality in 
XMG-treated (B6D2 XMG) mice. 
were prepared from B6 mice at different days during T. cruzi 
infection, and analyzed by Northern blot (Fig. 2). I1,10-specific 
mRNA was not detected in normal mouse spleens  or in spleens 
from mice infected for 2 or 4 d.  By day 8 after  infection, 
and continuing through day 15 after infection, a period cor- 
responding to  the  initiation  and  logarithmic increase  of 
parasitemia (Fig. 1 A), spleen cell I1-10 mRNA was present. 
This demonstrated that an increase in I1-10 mlLNA occurred 
in susceptible mice during the acute phase of T. cruzi infection. 
Production of  lLIO in Mice with T. cruzi Infection.  An IFN-3r 
inhibition assay was used to evaluate I1-10 activity in super- 
natants of cuhured spleen cells from infected B6 and B6D2 
mice. Spleen cells from mice infected for 6, 10, 14, or 17 d 
were cultured in vitro for 48 h and the supernatants tested 
for CSIF activity, the inhibition of IFN-'y production in re- 
sponse to recall antigenic stimulation (Fig. 3). The pattern 
of production of biologically active CSIF correlated directly 
with that seen for Ibl0 mRNA production. In addition, it 
was found that spleen cells from infected B6D2 mice did not 
produce detectable levels of CSIF. Similar results were ob- 
tained when spleen cells from either of the mouse groups 
were stimulated in vitro with T. cmzi trypomastigote lysate 
(data not shown). Thus, the production of biologically ac- 
tive CSIF was a distinguishing feature of acute, fatal infec- 
tions in this model. A neutralizing mAb (SXC1) was used 
for verification that the CSIF activity produced by spleen cells 
of infected B6 mice was due to II-10. The IFN-3~-inhibiting 
activity produced by spleen cells of acutely infected mice, as 
well as that of ri1-10,  was neutralized by anti-I1-10 mAb 
(Fig.  4). 
Effects oSII_,io on the Intracellular Inhibition ofT. cruzi.  Be- 
cause the course of acute T. cruzi infection depends largely 
on the degree of intracdlular replication of the parasite in 
host cells, including macrophages, the ability of IFN-3' to 
inhibit this replication is of fundamental importance in the 
mediation of resistance by this cytokine. Interference with 
Figure 2.  Northern blot for IL-10  in B6 mice during T. cruzi infection, 
15/tg total RNA extracted from spleen cells of uninfected (day 0) or in- 
fected (days 4,  8,  15, 19) per lane. Shown is a 7-d exposure. 
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Figure 3.  IblO activity in spleen cell supernatants from B6 ~lled bar) 
and B6D2 (stippled bar) mice infected with T. cruzi. 48-h supernatants of 
5  x  106 unstimuhted spleen cells from uninfected and from mice infected 
for 6-17 d with T. cruzi were assayed for CSIF activity. Representative 
data from two experiments are shown. Each point represents pooled spleen 
cells from three mice. Medium 
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Figure 4.  Anti-IL-10 blocks the IFN-3,-inhibiting  activity of superna- 
tants from spleen cells of B6 mice infected with T cruzi.  CSIF activity 
was determined using 10 U  rIL-10 (filled bar), a 1/20 dilution of spleen 
cell supernatant from mice infected 17 d (stippled bar), and mock cos call 
supernatant (hatched bar) in the absence or presence of SXC1 ascites (50 
/,g protein/ml). 
this process could be an important mechanism in pathogen- 
esis. We examined the ability of macrophages treated with 
rib10 to inhibit the intracellular replication of T, cruzi after 
activation with IFN-%  Preincubation of mouse peritoneal 
macrophages with rlL-10--containing  COS supernatant, but 
not with mock COS supernatant, significantly reduced the 
inhibitory effects of IFN-y on the intracellular replication 
of T cruzi (Table 1). Thus, in addition to the ability of II,-10 
to interfere with the antigen presentation by macrophages 
(31), this cytokine can also block macrophage activation to 
inhibit intracellular parasites.  This observation adds another 
important  dimension  to  the regulatory functions  of this 
cytokine. 
Discussion 
This study presents two findings relevant to mechanisms 
of host  resistance to  acute  T. cruzi  infection.  The first is 
documentation of the importance of IFN-3' in controlling 
acute infection by using genetically resistant mice. The second 
is  that  IL-10, an inhibitory cytokine, is  produced during 
T. cruzi infection. The latter observation may be an impor- 
tant step in understanding how this parasite escapes immune- 
mediated destruction. 
IFN-~/is an effective inhibitor of the in vitro replication 
of T. cruzi in macrophages (13-15,  17). IFN-3' can also re- 
verse the course of fatal infection in vivo in highly suscep- 
tible mice (17). More recently, it has been shown that treat- 
ment of susceptible mice with anti-IFN-3, can exacerbate 
infection (29).  Using genetically resistant B6D2 mice, we 
have shown in this study that in vivo inhibition of a single 
cytokine is sufficient to eliminate that resistance,  which es- 
tablishes the importance of endogenous IFN-~/in mediating 
host resistance to  T. cruzi infection. The question remains 
as to why IFN-y produced during T. cruzi infection fails to 
protect mice from disease. One possibility is the kinetics of 
the cytokine response. 
The importance of the early response to infection is illus- 
trated by in vivo experiments with IFN-3' and anti-IFN-% 
To consistently prevent the development of acute disease in 
mice, it is necessary to administer IFN-~/before day 4 of in- 
fection (17). Similarly, to produce fatal infections in resistant 
B6D2 mice, it was necessary to administer anti-IFN-y no 
later than 4 d after infection. These experiments may indi- 
cate the necessity of limiting the early replication of T. cruzi 
in host cells to obtain a healing response. They may also in- 
dicate the potential of IFN-3' to drive the development of 
a Thl type T  cell response. 
Another possible way in which cytokines may exacerbate 
infection is to inhibit the effects of protective cytokines, such 
Table  1.  rlL-lO Blocks the IFN-'y-mediated Inhibition of Trypanosoma cruzi in Mouse Peritoneal Macrophages 
Exp.  1  Exp.  2 
Amastigotes  Percent  Amastigotes  Percent 
IFN-y  /100 macrophages  inhibition  /100 macrophages  inhibition 
Medium 
COS-control 
rlL-10 
X  _+  SD  X  +_  SD 
-  33.1  •  3.9  137.9  _+  13.5 
+  5.6  +  0.6  83.1  41.1  +_ 8.7  70.2 
-  36.6  +_ 6.3  130.0  •  2.8 
+  3.5  _+  1.6  90.4  32.6  •  6.9  74.9 
-  30.5  •  1.7  166.8  •  20.6 
+  14.6  •  2.6  52.1  120.9  •  2.1  27.5 
BALB/c peritoneal macrophages were treated with rMu-IFN-'y and rIL-lO or COS-supernatant control for 48 h, 
trypomastigotes.  The cells were washed thoroughly 2 h later and incubated for 48 h (Exp. 1) or 72 h (Exp. 2) and 
ed.  IFN-'y and COS-control  +  IFN-~/groups vs.  rlL-lO  +  IFN-% p <  0.05. 
washed, and infected with T. cruz/ 
intracellular amastigotes enumerat- 
172  Interleukin 10 in Trypanosoraa cruzi  Infections as IFN-3,. We have recently shown that TGF-fl production 
is increased during acute T. cmzi infections, and that this mol- 
ecule can block the inhibitory effects of IFN-'Ir  both in vitro 
and in vivo (19). The present study demonstrates that IL-10 
has a similar deactivating function. Thus, I1.-10 may act to 
downregulate early IFN-3, production during T. cruzi infec- 
tion, as well as to inhibit its effects.  These results provide 
further information on the macrophage as a key target for 
the action of I1.10  (31,  31). 
The concomitant occurrence or balance of Thl and Th2 
responses must be considered in determining disease outcome. 
A  predominantly Thl  type response, characterized by the 
production of IFN-3, and I1.2, is associated with a healing 
response in experimental leishmania infections, while a Th2 
response, characterized by the cytokines I1.4, I1-5, I1.6, and 
I1.10,  is associated with disease exacerbation (32, 33).  The 
situation appears to be different in T. cruzi infection, where 
both a Thl response (IFN-3,) and a Th2 response (II.-10) occur 
during infection in susceptible mice. Thus, the infection ap- 
pears to be characterized by the production of cytokines which 
can counteract the beneficial Thl type response. The produc- 
tion of cytokines such as TGFq3 and I1.-10 may be the deciding 
factor in the outcome of T. cruzi infection. In support of this 
concept, production of IL-10 activity by spleen cells of in- 
fected B6 mice was elevated over that seen in identically in- 
fected B6D2 mice. Furthermore, it is possible that resistance 
or susceptibility to  acute infection is determined by early 
production of protective or exacerbative cytokines. 
77. cruzi infections in mice have provided an excellent model 
for the study of immune responses in acute and chronic in- 
fections. Studies on the regulation of cytokines during the 
course of infection as well the role of cytokines in host resis- 
tance and susceptibility have been performed with this model. 
It is of particular interest because T. cruzi survives and repli- 
cates in host macrophages, and evasion of killing mechanism 
by these ceils must be considered. Although these parasites 
have unique ways of escaping from the phagocytic vacuole 
which may contribute to their intracellular survival (34), mac- 
rophages activated by cytokines, such as IFN-% can effec- 
tively diminate intracellular infection. Thus, the inhibition 
of the production and/or effects of cytokines may be impor- 
tant parasite survival mechanisms which could be targets for 
therapeutic approaches. A recent study by Heinzel et al. (33) 
has demonstrated the production of II.-10 mRNA during mu- 
fine infections with leishmania. We report herein a similar 
finding in murine T. cruzi infections. In addition, we docu- 
ment the production of biologically active I1-10 by geneti- 
cally susceptible, but not resistant mice, and demonstrate that 
II.-10 may inhibit the antiparasite function of IFN-3,. 
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